BioMarin Pharmaceuticals
BMRN
BMRN
435 hedge funds and large institutions have $11.7B invested in BioMarin Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 170 increasing their positions, 161 reducing their positions, and 79 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
23% less capital invested
Capital invested by funds: $15.3B → $11.7B (-$3.53B)
27% less call options, than puts
Call options by funds: $81.3M | Put options by funds: $112M
56% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 79
Holders
435
Holding in Top 10
9
Calls
$81.3M
Puts
$112M
Top Buyers
| 1 | +$136M | |
| 2 | +$59.2M | |
| 3 | +$51.5M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$39.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.4M |
Top Sellers
| 1 | -$117M | |
| 2 | -$75.2M | |
| 3 | -$65.3M | |
| 4 |
HCM
Highline Capital Management
New York
|
-$52M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$51.6M |